78 related articles for article (PubMed ID: 38635315)
1. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
2. What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination.
Lynge E; Antilla A; Arbyn M; Segnan N; Ronco G
Eur J Cancer; 2009 Oct; 45(15):2714-21. PubMed ID: 19695870
[TBL] [Abstract][Full Text] [Related]
3. Projected Time for the Elimination of Cervical Cancer Under Various Intervention Scenarios: Age-Period-Cohort Macrosimulation Study.
Chen YC; Chen YY; Su SY; Jhuang JR; Chiang CJ; Yang YW; Lin LJ; Wu CC; Lee WC
JMIR Public Health Surveill; 2024 Apr; 10():e46360. PubMed ID: 38635315
[TBL] [Abstract][Full Text] [Related]
4. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
5. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
[TBL] [Abstract][Full Text] [Related]
6. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
7. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
[TBL] [Abstract][Full Text] [Related]
8. The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of human papillomavirus screening with self-collection and digital registry support.
Keane A; Ng CW; Simms KT; Nguyen D; Woo YL; Saville M; Canfell K
Int J Cancer; 2021 Dec; 149(12):1997-2009. PubMed ID: 34363620
[TBL] [Abstract][Full Text] [Related]
9. Incidence of gynaecological cancer during the COVID-19 pandemic: A population-based study in the Netherlands.
Oymans EJ; de Kroon CD; Bart J; Nijman HW; van der Aa MA
Cancer Epidemiol; 2023 Aug; 85():102405. PubMed ID: 37356263
[TBL] [Abstract][Full Text] [Related]
10. Forecast of a future leveling of the incidence trends of female breast cancer in Taiwan: an age-period-cohort analysis.
Chen YC; Su SY; Jhuang JR; Chiang CJ; Yang YW; Wu CC; Lin LJ; Lee WC
Sci Rep; 2022 Jul; 12(1):12481. PubMed ID: 35864141
[TBL] [Abstract][Full Text] [Related]
11. Forecast of peak attainment and imminent decline after 2017 of oral cancer incidence in men in Taiwan.
Jhuang JR; Su SY; Chiang CJ; Yang YW; Lin LJ; Hsu TH; Lee WC
Sci Rep; 2022 Apr; 12(1):5726. PubMed ID: 35388051
[TBL] [Abstract][Full Text] [Related]
12. Towards the elimination of cervical cancer in Taiwan.
Wu MH; Lin LJ; Wu CC
J Formos Med Assoc; 2022 Jul; 121(7):1188-1190. PubMed ID: 34865949
[No Abstract] [Full Text] [Related]
13. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
Falcaro M; Castañon A; Ndlela B; Checchi M; Soldan K; Lopez-Bernal J; Elliss-Brookes L; Sasieni P
Lancet; 2021 Dec; 398(10316):2084-2092. PubMed ID: 34741816
[TBL] [Abstract][Full Text] [Related]
14. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
15. Elimination of cervical cancer depends on HPV vaccination and primary HPV screening.
Harper DM; Jimbo M
Lancet Infect Dis; 2021 Oct; 21(10):1342-1344. PubMed ID: 34081924
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
